ERBB2 and lung adenocarcinoma: By contrast, pyrotinib revealed mPFS of 6.9 months and overall ORR of 30% in patients with HER2-mutant advanced lung adenocarcinoma as second-line or above therapy, especially, with a higher ORR of 27.3% for YVMA insertion (Zhou et al., 2020).